Clinical applications of RANK-ligand inhibition

Internal Medicine Journal

Volumn 39, Issue 2, 2009, Pages 110-116

  Romas, E ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Denosumab; OPG; Osteoclast; RANKL

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; COLONY STIMULATING FACTOR 1; DENOSUMAB; METHOTREXATE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR; ZOLEDRONIC ACID;

ADYNAMIC BONE DISEASE; BONE DISEASE; BONE EROSION; BONE METASTASIS; BONE REMODELING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GENE MUTATION; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; IDIOPATHIC HYPERPHOSPHATASIA; JAW OSTEONECROSIS; LIGAND BINDING; NONHUMAN; OSTEOCLASTOMA; OSTEOLYSIS; PAGET BONE DISEASE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROSTHESIS LOOSENING; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE DENSITY; BONE DEVELOPMENT; DRUG EFFECTS; METABOLISM; OSTEOBLAST; OSTEOPOROSIS; PHYSIOLOGY;

ANIMALS; BONE DENSITY; BONE RESORPTION; HUMANS; OSTEOBLASTS; OSTEOGENESIS; OSTEOPOROSIS; RANK LIGAND; SIGNAL TRANSDUCTION;

EID: 63849319368     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2008.01732.x     Document Type: Review

References (48)

1. Martin TJ, Seeman E. New mechanisms and targets in the treatment of bone fragility. Clin Sci 2007 112 : 77 91.
2. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000 21 : 115 37.
3. Teitelbaum SL. Osteoclasts: what do they do and how do they do it? Am J Pathol 2007 170 : 427 35.
4. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003 423 : 337 42.
5. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999 20 : 345 57.
6. Heider U, Zavrski I, Jakob C. Expression of receptor activator of NF-kappaB ligand (RANKL) mRNA in human multiple myeloma cells. J Cancer Res Clin Oncol 2004 130 : 469 74.
7. Franchimont N, Reenaers C, Lambert C. Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients. Clin Exp Immunol 2004 138 : 491 8.
8. Miranda-Carus ME, Benito-Miguel M, Balsa A. Peripheral blood T lymphocytes from patients with early rheumatoid arthritis express RANKL and interleukin-15 on the cell surface and promote osteoclastogenesis in autologous monocytes. Arthritis Rheum 2006 54 : 1151 64.
9. Simonet WS, Lacey DL, Dunstan CR. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997 89 : 309 19.
10. Kong YY, Yoshida H, Sarosi I. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999 397 : 315 23.
11. Li J, Sarosi I, Yan XQ. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A 2000 97 : 1566 71.
12. Bucay N, Sarosi I, Dunstan CR. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998 12 : 1260 68.
13. Mizuno A, Amizuka N, Irie K. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998 247 : 610 15.
14. Hamdy NA. Osteoprotegerin as a potential therapy for osteoporosis. Curr Osteoporos Rep 2005 3 : 121 5.
15. Bekker PJ, Holloway DL, Rasmussen AS. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004 19 : 1059 66.
16. Bekker PJ, Holloway DL, Rasmussen AS. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2005 20 : 2275 82.
17. Sambrook P, Cooper C. Osteoporosis. Lancet 2006 367 : 2010 18.
18. Weitzmann MN, Pacifici R. T cells: unexpected players in the bone loss induced by estrogen deficiency and in basal bone homeostasis. Ann N Y Acad Sci 2007 1116 : 360 75.
19. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003 111 : 1221 30.
20. McClung MR, Lewiecki EM, Cohen SB. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006 354 : 821 31.
21. Lewiecki EM, Miller PD, McClung MR. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 2007 22 : 1832 41.
22. Romas E, Gillespie MT, Martin TJ. Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone 2002 30 : 340 46.
23. Romas E, Gillespie MT. Inflammation-induced bone loss: can it be prevented? Rheum Dis Clin North Am 2006 32 : 759 73.
24. Romas E. Bone loss in inflammatory arthritis: mechanisms and therapeutic approaches with bisphosphonates. Best Pract Res Clin Rheumatol 2005 19 : 1065 79.
25. van der Heijde D, Cohen S, Sharp J. Denosumab inhibits RANKL, reducing progression of the total sharp score and bone erosions in patients with rheumatoid arthritis: 12-month X-ray results. Arthritis Rheum 2007 56 (Suppl S698.
26. Deodar A, Dore R, Sharp J. Denosumab-mediated increase of hand bone mineral density in patients with rheumatoid arthritis is associated with decreased progression of bone erosion. Arthritis Rheum 2007 56 (Suppl S944.
27. Romas E, Sims NA, Hards DK. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol 2002 161 : 1419 27.
28. Berenson JR, Rajdev L, Broder M. Pathophysiology of bone metastases. Cancer Biol Ther 2006 5 : 1078 81.
29. Silvestris F, Lombardi L, De Matteo M, Bruno A, Dammacco F. Myeloma bone disease: pathogenetic mechanisms and clinical assessment. Leuk Res 2007 31 : 129 38.
30. Hofbauer LC, Rachner T, Singh SK. Fatal attraction: why breast cancer cells home to bone. Breast Cancer Res 2008 10 : 101.
31. Roodman GD, Dougall WC. RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat Rev 2008 34 : 92 101.
32. Lipton A, Steger GG, Figueroa J. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007 25 : 4431 7.
33. Luftner D, Henschke P, Possinger K. Clinical value of bisphosphonates in cancer therapy. Anticancer Res 2007 27 : 1759 68.
34. Daubine F, Le Gall C, Gasser J, Green J, Clezardin P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 2007 99 : 322 30.
35. Menaa C, Reddy SV, Kurihara N. Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone. J Clin Invest 2000 105 : 1833 8.
36. Whyte MP. Paget's disease of bone and genetic disorders of RANKL/OPG/RANK/NF-kappaB signaling. Ann N Y Acad Sci 2006 1068 : 143 64.
37. Cundy T, Davidson J, Rutland MD, Stewart C, DePaoli AM. Recombinant osteoprotegerin for juvenile Paget's disease. N Engl J Med 2005 353 : 918 23.
38. Morgan T, Atkins GJ, Trivett MK. Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB. Am J Pathol 2005 167 : 117 28.
39. Purdue PE, Koulouvaris P, Potter HG, Nestor BJ, Sculco TP. The cellular and molecular biology of periprosthetic osteolysis. Clin Orthop Relat Res 2007 454 : 251 61.
40. Veigl D, Niederlova J, Krystufkova O. Periprosthetic osteolysis and its association with RANKL expression. Physiol Res 2007 56 : 455 62.
41. Black DM, Greenspan SL, Ensrud KE. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003 349 : 1207 15.
42. Finkelstein JS, Leder BZ, Burnett SM. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab 2006 91 : 2882 7.
43. Iwata K, Li J, Follet H, Phipps RJ, Burr DB. Bisphosphonates suppress periosteal osteoblast activity independently of resorption in rat femur and tibia. Bone 2006 39 : 1053 8.
44. Martin TJ, Sims NA. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 2005 11 : 76 81.
45. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005 90 : 1294 1301.
46. Goh SK, Yang KY, Koh JS. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 2007 89 : 349 53.
47. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008 358 : 1304 6.
48. Khosla S, Burr D, Cauley J. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007 22 : 1479 91.